Zoetis of Pfizer Inc Raises $2.2b in IPO

By Admin
Zoetis, which priced 86.1m shares at $26 according to Reuters, is now valued at a massive $13 billion. Shares in the company were expected to sell for...

 

Zoetis, which priced 86.1m shares at $26 according to Reuters, is now valued at a massive $13 billion. Shares in the company were expected to sell for between $22 and $25 each, have exceeded expectations. Zoetis sells pharmaceutical products for livestock and domestic pets.

Related news: Pfiser Zoetis Files IPO Statement

Raising over $2.2 billion in shares, Zoetis’ IPO is the largest for a US company since Facebook raised $16 billion last May. According to Reuters, the deal was between 10 and 20 times oversubscribed, meaning demand for the deal was very high.

The deal for Zoetis comes as its parent Pfizer, the world's biggest drug maker, is divesting its non-pharmaceuticals units in order to focus on its core prescription drugs business.

Last April, Pfizer sold its infant nutrition business to Nestle SA (NESN.VX) for $11.9 billion.

Source: Reuters

Share

Featured Articles

The Merck Group: Pharma's History & Innovation in India

Welcome back to part two of our exploration of The Merck Group's history and investment in China and India, with this part focusing on innovation in India

How CVS Health is Rising to the Omnichannel Challenge

US healthcare company CVS Health is reshaping its supply chain to meet the omnichannel needs of its customers

Kinaxis: Pharma Seeing Euro-wide Supply Chain Challenges

Supply chain specialist Kinaxis says UK pharma still recovering from Brexit and pandemic, and that Europe also seeing medicines value chain problems

Healthcare Digital Transformations Stymied by Data Silos

Digital Healthcare

McKinsey: Brain Health Underfunding 'a Global Concern'

Digital Healthcare

Endometriosis Linked to Heart Attacks & Strokes

Medical Devices & Pharma